RecruitingPrevent Whooping CoughPrevent DiphtheriaPrevent Tetanus
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Eligible age
0.2–0.3 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months.
Sponsor: Changchun BCHT Biotechnology Co.
You may qualify if…
- ✓ 1. Healthy infants and young children who are permanent residents aged 2 months (60-89 days), and can provide valid identification documents for the subject and their legal guardian;
- ✓ 2. Obtain the informed consent of the subject's legal guardian and sign the informed consent form;
- ✓ 3. The legal guardian of the subject can comply with the requirements of the clinical trial protocol.
You may not qualify if…
- ✕ 1. History of pertussis, diphtheria, or tetanus;
- ✕ 2. Contact with individuals diagnosed with pertussis or diphtheria within the past 30 days;
- ✕ 3. Vaccination with vaccines containing DTaP components, inactivated poliovirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine, or Hib vaccine;
- ✕ 4. Premature infants (born before 37 weeks of gestation), infants with severe abnormal labor processes or a history of asphyxia rescue, or low birth weight infants (\<2500g);
- ✕ 5. Axillary temperature \>37.0°C on the day of enrollment\*;
- ✕ 6. Severe congenital malformations or developmental disorders, genetic defects, severe malnutrition, or congenital diseases (such as Down syndrome, sickle cell anemia, congenital nervous system diseases, etc.);
- ✕ 7. History of epilepsy, convulsions, or seizures, history of cerebral palsy, or family history of mental illness;
- ✕ 8. Autoimmune diseases or immunodeficiencies (such as perianal abscesses suggesting possible immunodeficiency in infants, human immunodeficiency virus infection, lymphoma, leukemia, etc.), or parents/siblings with autoimmune diseases or immunodeficiencies;
Source: ClinicalTrials.gov · NCT07112144 · last updated 2025-08-08